| answer text |
<p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s
National Institute for Health Research Clinical Research Network (CRN) is providing
research infrastructure to enable molecular genetic analysis of HS, although expenditure
on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information
on the diagnosis, treatment care and support of patients with HS can be found on the
NHS Choices website. This also provides links to the British Association of Dermatologists,
which has produced a patient information leaflet on HS, and the HS Trust, which is
the United Kingdom‘s leading charity for the condition. More information can be found
at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx"
target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p>
</p><p><br> In terms of the care pathway for the condition, HS can usually be managed
with treatments including antibiotics, antiseptic washes and immunosuppressive treatments
such as steroids or ciclosporin, which a general practitioner may prescribe. For those
patients with the most serious forms of HS who cannot be managed through routine access
to treatments provided through primary or secondary care, a referral to a specialised
dermatology service may be appropriate. NHS England commissions services for people
with rare and complex skin conditions and has set out what providers must have in
place in order to offer specialist dermatology care. These services may provide more
intensive therapies with the involvement of a range of health and care professionals,
subject to a patient’s needs. More information can be found at the following link:</p><p>
</p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf"
target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p>
</p>
|
|
